In late December 2025, Sanofi secured European Commission approval for Wayrilz (rilzabrutinib), the first BTK inhibitor for ...
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...
Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...
Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...
Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...
Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...
A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...
Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback